Glaspy J - Search Results

1

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.

McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Among authors: glaspy j. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.

2

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. Among authors: glaspy ja. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.

3

Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media.

Paquette RL, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J. Paquette RL, et al. Among authors: glaspy j. J Hematother. 1998 Dec;7(6):481-91. doi: 10.1089/scd.1.1998.7.481. J Hematother. 1998. PMID: 9919941

4

Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer.

Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. Paquette RL, et al. Among authors: glaspy ja. Blood. 2000 Oct 1;96(7):2385-90. Blood. 2000. PMID: 11001888 Free article.

5

Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery.

Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. Paquette RL, et al. Among authors: glaspy ja. Exp Hematol. 2002 Apr;30(4):374-80. doi: 10.1016/s0301-472x(02)00770-1. Exp Hematol. 2002. PMID: 11937274 Free article. Clinical Trial.

6

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. Butterfield LH, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5902-8. Clin Cancer Res. 2003. PMID: 14676113 Clinical Trial.

7

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Kobayashi N, et al. Among authors: glaspy ja. Clin Cancer Res. 2006 Aug 1;12(15):4662-70. doi: 10.1158/1078-0432.CCR-06-0459. Clin Cancer Res. 2006. PMID: 16899616 Free PMC article.

8

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Ribas A, et al. Among authors: glaspy ja. Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783. Clin Cancer Res. 2009. PMID: 19118070

9

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Ribas A, et al. Among authors: glaspy ja. Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789309 Free PMC article. Clinical Trial.

10

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. Tap WD, et al. Among authors: glaspy ja. Neoplasia. 2010 Aug;12(8):637-49. doi: 10.1593/neo.10414. Neoplasia. 2010. PMID: 20689758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page